VIBATIV Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vibativ, and when can generic versions of Vibativ launch?
Vibativ is a drug marketed by Cumberland and is included in one NDA. There is one patent protecting this drug.
This drug has thirty-three patent family members in eighteen countries.
The generic ingredient in VIBATIV is telavancin hydrochloride. One supplier is listed for this compound. Additional details are available on the telavancin hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Vibativ
Vibativ was eligible for patent challenges on September 11, 2013.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 1, 2027. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
US Patents and Regulatory Information for VIBATIV
VIBATIV is protected by one US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of VIBATIV is ⤷ Start Trial.
This potential generic entry date is based on patent 7,531,623.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | DISCN | Yes | No | 7,531,623 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-002 | Sep 11, 2009 | RX | Yes | Yes | 7,531,623 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for VIBATIV
See the table below for patents covering VIBATIV around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Argentina | 035333 | GLUCOPEPTIDO SUSTITUIDO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, SU USO EN LA FABRICACION DE MEDICAMENTOS UTILES PARA TRATAR ENFERMEDADES BACTERIANAS Y METODO PARA PREPARAR DICHOS COMPUESTOS. | ⤷ Start Trial |
| Austria | 337334 | ⤷ Start Trial | |
| Austria | 388960 | ⤷ Start Trial | |
| Austria | 402951 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VIBATIV
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1292612 | CA 2011 00033 | Denmark | ⤷ Start Trial | PRODUCT NAME: TELAVANCIN, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER TELAVANCIN HYDROCHLORID |
| 1292612 | 122011100062 | Germany | ⤷ Start Trial | PRODUCT NAME: TELAVANCIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ HIERVON, EINSCHLIESSLICH TELAVANCINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902 |
| 1292612 | 132012902025885 | Italy | ⤷ Start Trial | PRODUCT NAME: TELAVANCINA(VIBATIV); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/11/705/001-002, 20110902 |
| 1292612 | SPC/GB11/056 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: TELAVANCIN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TELAVANCIN HYDROCHLORIDE; REGISTERED: UK EU/1/11/705/001 20110906; UK EU/1/11/705/002 20110906 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch